Navigation Links
Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older
Date:7/18/2011

SAN DIEGO, July 18, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced the commercial launch of DIFICID™ (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in patients 18 years of age and older. In two large Phase 3 clinical studies, DIFICID had clinical response rates at the end of the 10-day treatment period that were non-inferior to oral vancomycin. In addition, DIFICID was superior to vancomycin in sustained clinical response, defined as clinical response at the end of treatment and survival without proven or suspected CDAD recurrence through 25 days beyond the end of treatment. With the commercial availability of DIFICID, Optimer is initiating a Patient Assistance Program to help eligible uninsured and underinsured patients gain access to this important treatment option. DIFICID is the only FDA-approved treatment for CDAD that has demonstrated superiority to vancomycin in sustained clinical response and the first new drug approved for the treatment of CDAD in more than 25 years.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

"Patient access to DIFICID is Optimer's highest priority. For eligible patients, the Patient Assistance Program will help expand access to DIFICID for those patients in need," said Pedro Lichtinger, President and Chief Executive Officer of Optimer. "We have assembled a world class hospital-based product launch team in the U.S., including expertise in access, reimbursement, health economics, medical education, sales and marketing that we believe when combined with Cubist, our co-promotion partner in the U.S., will make the DIFICID launch one of the most impactful in the hospital segment. This team will help bring to patients a new option proven to provide superior sustained cl
'/>"/>

SOURCE Optimer
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2. Optimer Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
3. Optimer Pharmaceuticals Reports First Quarter 2011 Financial Results
4. Optimer Pharmaceuticals Expands Senior Management Team
5. Optimer Pharmaceuticals to Present at May 2011 Investor Conferences
6. Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States
7. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
8. Trading Halted Today in Optimer Pharmaceuticals Stock
9. Optimer Pharmaceuticals Announces Presentation at SHEA of Data Highlighting the Burden of Clostridium difficile Infection (CDI) in Hospital Patients
10. Optimer Pharmaceuticals Announces Presentation at Upcoming SHEA Annual Meeting Regarding Hospital CDI Patients at Risk of Recurrence and Mortality
11. Optimer Pharmaceuticals Announces Issuance of Key Patent Covering Fidaxomicin Methods of Use as a Treatment of Clostridium difficile infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)...   ViaDerma, Inc. (OTCQB: VDRM), a ... to market, has recently released a revolutionary new ... topical liquid tetracycline-based antibiotic that uses a patent-pending ... medication active ingredients into topical drugs. The drug ... to help prevent skin infection in minor cuts, ...
(Date:10/30/2014)... , Oct. 30, 2014  Nektar Therapeutics (Nasdaq: ... the third quarter ended September 30, 2014 on Thursday, ... markets. Howard Robin , president and chief executive ... results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. ... and a live audio-only Webcast of the conference call ...
(Date:10/30/2014)...   BioLife Solutions , Inc. (NASDAQ: ... proprietary clinical grade hypothermic storage and ... products for cells and tissues, today announced today ... be released on Thursday, November 6, 2014, and that ... webcast at 1:30 p.m. PST that afternoon. Management will ...
Breaking Medicine Technology:ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2BioLife Solutions to Report Financial Results for Third Quarter 2014 and Provide Business Update on November 6, 2014 2
... Support Development,of Omega DUROS Continuous Delivery Therapy, ... Intarcia,Therapeutics, Inc., a privately held biopharmaceutical company,today ... study of omega,interferon with or without ribavirin ... C. The results demonstrate that,omega interferon in ...
... Conn., April 12, 2007 /PRNewswire-FirstCall/ --,CuraGen Corporation ... (PXD101), a histone deacetylase (HDAC) inhibitor being,investigated ... a protein,being investigated for the prevention of ... upcoming American Association for Cancer,Research (AACR) 2007 ...
Cached Medicine Technology:Intarcia Therapeutics Announces Final Results From a Phase 2 Study,of Injectable Omega Interferon plus Ribavirin for the Treatment of,Hepatitis C Genotype-1 2Intarcia Therapeutics Announces Final Results From a Phase 2 Study,of Injectable Omega Interferon plus Ribavirin for the Treatment of,Hepatitis C Genotype-1 3Intarcia Therapeutics Announces Final Results From a Phase 2 Study,of Injectable Omega Interferon plus Ribavirin for the Treatment of,Hepatitis C Genotype-1 4CuraGen Announces New Preclinical Results with Belinostat and,Velafermin to be Presented at AACR Annual Meeting 2CuraGen Announces New Preclinical Results with Belinostat and,Velafermin to be Presented at AACR Annual Meeting 3CuraGen Announces New Preclinical Results with Belinostat and,Velafermin to be Presented at AACR Annual Meeting 4
(Date:10/30/2014)... Dr. Joseph Furlin MD, a certified obstetrician and gynecologist, has ... GYN in Melrose Park, IL and OB GYN ... about each of the care services and practice areas that ... and Spanish. The navigation of the website is easy ... Dr. Furlin’s patients with important information regarding his care methods ...
(Date:10/30/2014)... 2014 Global prebiotics market is expected ... a new study by Grand View Research, Inc. Positive ... sugar and fat free products owing to increased concerns ... prebiotics over the forecast period. , View full report ... & beverage was the largest application segment with market ...
(Date:10/30/2014)... 2014 REV'D Provision Co. announced today ... through a unique service called, The Feed . ... the everyday athlete. The Feed has taken the nutritional ... a system to pass that information on to the ... now available on The Feed!” says REV’D® marketing manager ...
(Date:10/30/2014)... New York (PRWEB) October 30, 2014 ... Society (NAMS) came to a close on Saturday, ... meeting since the Society’s inception in 1989. NAMS is ... health and quality of life of all women during ... healthy aging. With over 2,000 physicians and thought leaders ...
(Date:10/30/2014)... 2014 Sound Telecom, a leader in the ... assist people any time they wonder, “Should I use an ... by leading them through a series of yes or no ... query. , There are many considerations and scenarios that come ... answering service . This decision infographic serves as a ...
Breaking Medicine News(10 mins):Health News:Dr. Joseph Furlin Launches New Website with Information about Care Services 2Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 2Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 3Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 4Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 5Health News:Nutrition Experts at TheFeed.com Get REV'D 2Health News:Nutrition Experts at TheFeed.com Get REV'D 3Health News:Highlights from The North American Menopause Society 25th Annual Meeting 2Health News:Highlights from The North American Menopause Society 25th Annual Meeting 3Health News:Sound Telecom Produces Decision Infographic to Aid Businesses 2
... disorder, arterial trouble , FRIDAY, Oct. 12 (HealthDay News) ... pressure (CPAP) to treat people with obstructive sleep apnea ... the arteries -- within months, a new study finds. ... a direct link between obstructive sleep apnea and atherosclerosis, ...
... Calif., Oct. 12 Yesterday,Governor Schwarzenegger signed into ... to service and extend benefits to children and ... permanency. One important bill in this,package of legislation ... the current system of group home care into ...
... 12 The Agency for,Healthcare Research and Quality, part ... today the award of $41.6 million over the next ... centers as part of its,Centers for Education and Research ... the CERTs program. "Expanding the Centers for Education ...
... Shown to Prevent Post-Meal Oxidative Stress, FRESNO, Calif., ... It is probably a good idea based on health ... Health Effects of,Fruits and Vegetables in Houston, Texas this ... foods should be,consumed with each meal to prevent periods ...
... with the confusion of ... to their children, CINCINNATI, Oct. 12 All too ... give our children, especially,when it comes to the readily available ... as a frightening, but,important reminder that no medicine comes without ...
... Prior to Stroke, CLEVELAND, Oct. 12 Carotid ... today, are a significant risk factor,for stroke but many ... ultrasound screening is a successful tool for revealing,blocked carotid ... before death or,disability occurs. Life Line Screening, the ...
Cached Medicine News:Health News:Sleep Apnea Treatment Helps Stave Off Heart Disease 2Health News:California Alliance Applauds Governor's Support of Group Home Reform for Foster Youth 2Health News:California Alliance Applauds Governor's Support of Group Home Reform for Foster Youth 3Health News:AHRQ Expands Therapeutics Education and Research Centers and Adds New Topics: Health IT, Economics, Formularies 2Health News:AHRQ Expands Therapeutics Education and Research Centers and Adds New Topics: Health IT, Economics, Formularies 3Health News:Grape Consumption Improves Antioxidant Capacity in Humans 2Health News:Dr. Laura Jana Offers Parents Five Key Ways to Ensure Accurate Dosing of Liquid Medication to Infants 2Health News:Dr. Laura Jana Offers Parents Five Key Ways to Ensure Accurate Dosing of Liquid Medication to Infants 3Health News:Dr. Laura Jana Offers Parents Five Key Ways to Ensure Accurate Dosing of Liquid Medication to Infants 4Health News:Asymptomatic Carotid Artery Blockage a Significant Stroke Risk 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: